Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
Overview
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
Full Title of Study: “A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: December 2003
Detailed Description
The duration of treatment is 8 weeks.
Interventions
- Drug: aprepitant
- Drug: Comparator: placebo (unspecified)
Clinical Trial Outcome Measures
Primary Measures
- HAMD-17 total score at week 8. Tolerability.
- Time Frame: at week 8
Secondary Measures
- CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8
- Time Frame: at week 8
Participating in This Clinical Trial
Patients with Major Depressive Disorder
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Medical Monitor, Study Director, Merck Sharp & Dohme LLC
References
Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? J Psychiatr Res. 2008 Jul;42(8):622-30. doi: 10.1016/j.jpsychires.2007.07.003. Epub 2007 Sep 7.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.